Diamond Hill Capital Management Inc. Sells 708,204 Shares of Humana Inc. (NYSE:HUM)

Diamond Hill Capital Management Inc. lessened its stake in shares of Humana Inc. (NYSE:HUM) by 89.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 85,294 shares of the insurance provider’s stock after selling 708,204 shares during the quarter. Diamond Hill Capital Management Inc. owned approximately 0.07% of Humana worth $21,640,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Ashton Thomas Securities LLC bought a new stake in Humana during the 3rd quarter valued at $31,000. FPC Investment Advisory Inc. bought a new stake in Humana during the 4th quarter valued at $27,000. Centricity Wealth Management LLC bought a new stake in Humana during the 4th quarter valued at $30,000. LFA Lugano Financial Advisors SA boosted its stake in Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock valued at $32,000 after acquiring an additional 45 shares in the last quarter. Finally, OFI Invest Asset Management acquired a new stake in Humana in the fourth quarter valued at approximately $33,000. Institutional investors own 92.38% of the company’s stock.

Humana Price Performance

Shares of NYSE HUM opened at $251.32 on Friday. The stock has a market capitalization of $30.33 billion, a price-to-earnings ratio of 25.26, a PEG ratio of 2.05 and a beta of 0.57. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $406.46. The firm’s 50 day simple moving average is $271.56 and its 200-day simple moving average is $281.21. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76.

Humana (NYSE:HUM) last issued its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. Analysts expect that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a dividend of $0.885 per share. The ex-dividend date is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.41%. Humana’s payout ratio is 35.58%.

Insider Transactions at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now directly owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on HUM shares. Morgan Stanley lowered their target price on shares of Humana from $301.00 to $285.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 12th. Truist Financial raised their target price on shares of Humana from $260.00 to $290.00 and gave the company a “hold” rating in a research note on Monday, January 6th. Cantor Fitzgerald restated a “neutral” rating and issued a $290.00 target price on shares of Humana in a research note on Wednesday, February 12th. Piper Sandler raised their target price on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research note on Wednesday, January 15th. Finally, StockNews.com downgraded shares of Humana from a “buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Nineteen research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $285.68.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.